NASDAQ OMX

Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates

Dela

Four late-stage trials underway, targeting schizophrenia, major depressive disorder and insomnia disorder

Planning for commercialization moves forward 

Management to host conference call today at 8:30 a.m. Eastern Time

WALTHAM, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat unmet medical needs of central nervous system (CNS) disorders, today reported key business updates and financial results for the fourth quarter and fiscal year ended December 31, 2017.

"We have initiated four late-stage clinical efficacy trials with two compounds during late 2017, and we are planning to initiate a fifth with a third compound in the near future," said Dr. Remy Luthringer, executive chairman and chief executive officer of Minerva.  "We have also expanded our internal capabilities in the areas of strategic development, market research and commercial expertise as we plan for the transition from late-stage clinical development to the market for our product candidates," said Dr. Luthringer.  "This evolution supports our corporate strategy to develop and commercialize first-in-class products with novel mechanisms of action that address critical needs in targeted CNS areas, led by roluperidone (MIN-101) for negative symptoms in patients with schizophrenia." 

Roluperidone (MIN-101):

  • In December 2017, the first patient was screened in the pivotal Phase 3 clinical trial of roluperidone as monotherapy for negative symptoms in patients diagnosed with schizophrenia.  This multicenter, randomized, double-blind, parallel-group, placebo-controlled, 12-week trial will evaluate the efficacy and safety of 32 milligrams (mg) and 64 mg of roluperidone in adult patients with negative symptoms of schizophrenia.  The 12-week study will be followed by a 40-week, open-label extension period during which patients on drug will continue receiving their original dose and patients on placebo will receive either 32 mg or 64 mg of roluperidone.
     
  • The effect of roluperidone as compared to placebo will be determined with respect to the primary endpoint, the change from baseline in negative symptoms using the Positive and Negative Syndrome Scale (PANSS) Marder's negative symptoms factor score (NSFS) over the 12-week double-blind treatment period.  The key secondary endpoint is the effect of roluperidone compared to placebo as measured by the change from baseline in the Personal and Social Performance (PSP) total score over the same period.  Additional secondary endpoints will be the Clinical Global Impression of Severity (CGI-S) score and safety and tolerability.
     
  • Approximately 500 patients are expected to be enrolled at approximately 60 clinical sites in the U.S. and Europe, with about 30 percent of patients coming from the U.S.  Top-line results from the 12-week double blind phase of this trial are expected in the first half of 2019.

Seltorexant (MIN-202 or JNJ-42847922), under joint development with Janssen Pharmaceutica NV (Janssen):

  • In September 2017, the first patient was enrolled in a Phase 2b multi-center, double-blind, randomized, parallel-group, placebo-controlled, adaptive-dose finding clinical trial of seltorexant as adjunctive therapy to antidepressants in adult patients with major depressive disorder (MDD) who have responded inadequately to antidepressant therapy.  The primary objectives of this study are: (1) to assess the dose-response relationship and augmentation of antidepressant effect of up to three doses of seltorexant (10 mg, 20 mg, and 40 mg), and (2) to assess the safety and tolerability of seltorexant compared to placebo.  Approximately 280 patients are planned to be enrolled at more than 85 clinical sites in the U.S., Europe, Russia and Japan.
     
  • In December 2017, the first patient was enrolled in a Phase 2b multi-center, double-blind, randomized, parallel-group, active- and placebo-controlled dose finding clinical trial of seltorexant in patients with insomnia disorder.  The primary objective is to assess the dose-response of three doses of seltorexant (5, 10 and 20 milligrams daily) compared to placebo on sleep onset as measured by the latency to persistent sleep using polysomnography (PSG).  The key secondary objective is to assess the dose-response of these three doses compared to placebo on wake after sleep onset over the first six hours using PSG.  In addition, the effects of seltorexant on sleep and cognition will be compared to those effects of zolpidem to determine potential differences between the compounds.  Approximately 360 patients are planned to be randomized at clinical sites in the U.S., European Union and Japan.  
     
  • In December 2017, the first patient was enrolled in a Phase 2b multi-center, double-blind, randomized, flexible-dose, parallel-group study to assess the efficacy of flexibly dosed seltorexant compared to flexibly dosed quetiapine as adjunctive therapy to a baseline antidepressant drug in delaying time to all-cause discontinuation of study drug over a 6-month treatment period.  Approximately 100 patients are planned to be randomized at approximately 34 sites in the U.S. to receive either flexibly dosed seltorexant, 20 mg or 40 mg, or flexibly dosed quetiapine XR, 150 mg or 300 mg.
     
  • Under the amended agreement with Janssen that became effective in August, 2017, Janssen has waived its right to royalties on seltorexant insomnia sales in the Minerva territory (the European Union, Switzerland, Liechtenstein, Iceland and Norway).  Minerva retains all of its rights to seltorexant, including commercialization for the treatment of insomnia and as an adjunctive therapy for MDD, which includes an exclusive license in the Minerva Territory.  Minerva has also assumed strategic control for the clinical development of seltorexant in insomnia but has no further financial obligations until the Phase 2b development milestone is complete, which is expected to occur in the second half of 2019.  

MIN-117:

  • Building upon the results of an earlier Phase 2a trial with MIN-117 in Europe, the Company is planning to initiate a Phase 2b trial in MDD in the U.S. and Europe in early 2018.  The Company expects to enroll patients with MDD who also have symptoms of anxiety.  In preparation for this trial, a food effect study was recently completed, and no food effect was observed on the PK exposure parameters, therefore allowing dosing with or without food.

MIN-301:

  • The Company is continuing the pre-clinical development of MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein, for the treatment of Parkinson's disease and potentially for other neurodegenerative disorders. The next planned steps in this program include the completion of the pre-clinical package to enable the filing of an Investigational New Drug application (IND) in the U.S. and/or an Investigational Medicinal Product Dossier in Europe, and pending acceptance by regulatory authorities, the initiation of Phase 1 clinical testing thereafter.

             
Fourth Quarter and Year Ended 2017 Financial Results
             

  • Net Income (Loss):  Net income was $0.2 million for the fourth quarter of 2017, or income per share of $0.00 (basic and diluted), compared to a net loss of $9.4 million for the fourth quarter of 2016, or a loss per share of $0.27 (basic and diluted).  Net loss was $31.5 million for the year ended December 31, 2017, or a loss per share of $0.83 (basic and diluted), compared to a net loss of $31.0 million, or a loss per share of $0.99 (basic and diluted), for the year ended December 31, 2016.
     
  • R&D Expenses: Research and development (R&D) expenses were $6.5 million in the fourth quarter of 2017 and 2016.  R&D expenses were $30.3 million for the year ended December 31, 2017, compared to $20.4 million for the year ended December 31, 2016.  This increase in R&D expenses primarily reflects higher development expenses under the seltorexant program, increased expenses for the MIN-101 program, an increase in personnel costs and an increase in non-cash stock-based compensation expenses. These amounts were partially offset by lower costs due to the completion of the Phase 2a clinical trial of MIN-117.
     
  • G&A Expenses: General and administrative (G&A) expenses were $3.0 million in the fourth quarter of 2017, compared to $2.7 million in the fourth quarter of 2016.  G&A expenses were $10.9 million for the year ended December 31, 2017, compared to $9.8 million for the year ended December 31, 2016.  The increase in general and administrative expenses was primarily due to an increase in professional fees and an increase in non-cash stock-based compensation expenses.
     
  • Benefit for income taxes: Benefit for income taxes was $9.4 million in the fourth quarter of 2017, compared to zero in the fourth quarter of 2016. Benefit for income taxes was $9.4 million for the year ended December 31, 2017, compared to zero for the year ended December 31, 2016. On December 22, 2017, the United States enacted tax reform legislation commonly known as the Tax Cuts and Jobs Act (the "Act"), resulting in significant modifications to existing law. In the year ended December 31, 2017, these tax reforms resulted in a benefit of $9.4 million related to future implications of indefinite lived deferred tax positions.  
     
  • Cash Position: Cash, cash equivalents and marketable securities as of December 31, 2017 were approximately $133.2 million, compared to $83.0 million as of December 31, 2016.  During 2017, the Company received approximately $41.6 million in net proceeds from a July 2017 public offering of common stock, proceeds from the exercise of common stock warrants of $9.4 million, proceeds from the exercise of common stock options of $1.1 million, and $30 million in an upfront payment in connection with the amendment to the Company's Co-Development and License Agreement with Janssen for seltorexant. Minerva presently expects that its existing cash and cash equivalents will be sufficient to meet its anticipated capital requirements for at least the next 12 months from today.  The assumptions upon which this estimate is based are routinely evaluated and may be subject to change. 

Conference Call Information:

Minerva Neurosciences will host a conference call and live audio webcast today at 8:30 a.m. Eastern Time to discuss the quarter and recent business activities.  To participate, please dial (877) 312-5845 (domestic) or (765) 507-2618 (international) and refer to conference ID 1581007.

The live webcast can be accessed under "Events and Presentations" in the Investors and Media section of Minerva's website at ir.minervaneurosciences.com.  The archived webcast will be available on the website beginning approximately two hours after the event for 90 days.

About Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases.  Minerva's proprietary compounds include: roluperidone (MIN-101), in Phase 3 clinical development for schizophrenia; seltorexant (MIN-202 or JNJ-42847922) in Phase 2b clinical development for insomnia and major depressive disorder (MDD); MIN-117, in clinical development for MDD; and MIN-301, in pre-clinical development for Parkinson's disease.  Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV."  For more information, please visit www.minervaneurosciences.com

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended.  Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of this press release, and involve certain risks and uncertainties.  Forward-looking statements include statements herein with respect to the timing and scope of future clinical trials and results of clinical trials with roluperidone, seltorexant, MIN-117 and MIN-301; the timing and scope of future clinical trials and results of clinical trials with these compounds; the clinical and therapeutic potential of these compounds; the timing and outcomes of future interactions with U.S. and foreign regulatory bodies; our ability to successfully develop and commercialize our therapeutic products; the sufficiency of our current cash position to fund our operations; and management's ability to successfully achieve its goals.  These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether roluperidone, seltorexant, MIN-117 and MIN-301 will advance further in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether any of our therapeutic products will be successfully marketed if approved; whether any of our therapeutic product discovery and development efforts will be successful; management's ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions.  These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption "Risk Factors" in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission on March 12, 2017.  Copies of reports filed with the SEC are posted on our website at www.minervaneurosciences.com. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.   

   
CONDENSED CONSOLIDATED BALANCE SHEET DATA  
(Unaudited)  
  December 31, December 31,  
  2017     2016    
  (in thousands)  
ASSETS  
Current Assets:      
Cash and cash equivalents $   26,052   $   82,981    
Marketable securities     102,109       -     
Restricted cash     80       80    
Prepaid expenses and other current assets     1,299       803    
Total current assets     129,540       83,864    
Marketable securities - noncurrent     5,023       -     
Equipment, net     51       10    
Other non-current assets     15       -     
In-process research and development     34,200       34,200    
Goodwill     14,869       14,869    
Total Assets $   183,698   $   132,943    
       
LIABILITIES AND STOCKHOLDERS' EQUITY  
Current Liabilities:      
Notes payable - current portion $   3,962   $   4,854    
Accounts payable     1,436       1,467    
Accrued expenses and other current liabilities     1,439       816    
Accrued collaborative expenses     -        2,548    
Total current liabilities     6,837       9,685    
Long-Term Liabilities:      
Notes payable - noncurrent     -        3,841    
Deferred taxes     4,057       13,434    
Deferred revenue     41,176       -     
Other non-current liabilities     30       -     
Total liabilities     52,100       26,960    
Stockholders' Equity:      
Common stock     4       4    
Additional paid-in capital     295,975       238,837    
Accumulated deficit     (164,381 )     (132,858 )  
Total stockholders' equity     131,598       105,983    
Total Liabilities and Stockholders' Equity $   183,698   $   132,943    
       

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS      
(Unaudited)            
    Three Months Ended December 31,   Twelve Months Ended December 31,
    (in thousands, except per share amounts)   (in thousands, except per share amounts)
      2017     2016       2017     2016  
             
Revenues   $   -    $   -      $   -    $   -   
Operating expenses:            
Research and development       6,541       6,499         30,256       20,440  
General and administrative       2,991       2,739         10,914       9,751  
Total operating expenses       9,532       9,238         41,170       30,191  
             
Foreign exchange losses       (11 )     4         (57 )     (23 )
Investment income       434       61         942       198  
Interest expense       (105 )     (232 )       (614 )     (1,030 )
Loss before income taxes       (9,214 )     (9,405 )       (40,899 )     (31,046 )
Benefit for income taxes       (9,376 )     -          (9,376 )     -   
Net income (loss)   $   162   $   (9,405 )   $   (31,523 ) $   (31,046 )
Loss per share:            
Basic and diluted   $   0.00   $   (0.27 )   $   (0.83 ) $   (0.99 )
Weighted average shares:            
Basic and diluted       38,710       34,852         37,937       31,514  
             

Contact :

William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376

 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board17.9.2018 08:00Pressmeddelande

Press Release 17 September 2018 Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board Immunicum AB (publ; IMMU.ST) announced today the appointment of leading oncology experts to its Scientific Advisory Board with the addition of Pawel Kalinski, MD, PhD, Vice Chair for Translational Research within the Department of Medicine at Roswell Park Comprehensive Cancer Center, and Inge Marie Svane, MD, PhD, Professor, Head of the Clinical Cancer Research programme, Faculty of Health Sciences, University of Copenhagen, Director, Centre for Cancer Immunotherapy (CCIT), and consultant in Oncology, Herlev University Hospital. Both Scientific Advisory Board members will serve as a strategic resource to Immunicum as the company continues to advance the clinical development of its lead product, ilixadencel. "We are honored to have such highly specialized experts in the field of immuno-oncology and cell therapy join our Scientific Advisory Board a

Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet17.9.2018 08:00Pressmeddelande

Pressmeddelande 17 september 2018 Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet Immunicum AB (publ; IMMU.ST) meddelade i dag att två ledande immun-onkologiska experter har valts in i bolagets vetenskapliga råd för att fungera som strategiska resurser för Immunicum under bolagets fortsatta kliniska utveckling av sin ledande produkt, ilixadencel. Pawel Kalinski, MD, PhD, vice ordförande för translationell forskning vid den medicinska institutionen vid Roswell Park Comprehensive Cancer Center, och Inge Marie Svane, MD, PhD, professor, chef för det kliniska cancerforskningsprogrammet på medicinska fakulteten vid Köpenhamns universitet, chef för Center för cancerimmunterapi (CCIT) samt överläkare inom onkologi, Herlevs universitetssjukhus har valts in i rådet. - Vi är hedrade att ha experter med specialistkompetens inom området immunonkologi och cellterapi i vårt vetenskapliga råd, vilka kan erbjuda ytterligare vägledning när det

Hoylu AB: HOYLU HIRES NEW CTO, SATOSHI NAKAJIMA AND ANNOUNCES EXPANSION INTO JAPAN14.9.2018 08:30Pressmeddelande

Malmo, Sweden, September 14, 2018 - Hoylu, a leading enterprise collaboration company, announced today Satoshi Nakajima will join Hoylu in the newly created position, as Chief Technology Officer and President of Hoylu Japan. Nakajima will guide the strategic technology direction and innovation of Hoylu while also leading the new Hoylu office in Tokyo, Japan. "Satoshi is a visionary and world-class technologist who has substantial experience in delivering world class innovations. He is joining the Company as we are extending our reach and expanding into Japan," said Stein Revelsby, CEO. "Satoshi's extensive experience in strategy and delivering technology that support a great user experience will make an immediate impact on the company." Nakajima will serve as President of Hoylu Japan and will report to Stein Revelsby. His leadership will strengthen customer relations and help develop new business among emerging and established Japanese companies while strengthening the global position

Hoylu AB: HOYLU ANSTÄLLER SATOSHI NAKAJIMA SOM NY CTO OCH EXPANDERAR TILL JAPAN14.9.2018 08:30Pressmeddelande

Malmö, Sverige, 14 september 2018 - Hoylu, ett ledande företag inom samarbetsmjukvara för företagsmarknaden annonserar idag att Satoshi Nakajima tar anställning som CTO (Chief Technology Officer) och President för Hoylu Japan. Nakajima kommer styra den strategiska inriktningen för företagets produkter och leda innovationsarbetet. Han kommer också leda Hoylus nyöppnade kontor i Tokyo, Japan. Satoshi är en visionär teknologiexpert som har stor erfarenhet av att skapa innovativa lösningar. Han kommer till Hoylu samtidigt som vi utökar marknaden till att även täcka in Japan säger Stein Revelsby, VD. "Satoshis långa och gedigna erfarenhet i strategiska frågor och tekniska lösningar med fokus på användarupplevelse kommer få stor betydelse för oss." Nakajima kommer även att bli President för Hoylu Japan och kommer rapportera till Stein Revelsby. Hans ledarskap kommer stärka existerande kundrelationer och utveckla nya affärer på den japanska marknaden och samtidigt bidra till att flytta fram p

LeoVegas AB: LeoVentures invests in esports betting - Pixel.bet13.9.2018 08:45Pressmeddelande

The LeoVegas Group, through its wholly owned investment company LeoVentures Ltd, has acquired 51% of the shares in Pixel Holding Group Ltd, which runs the esports betting operator Pixel.bet. The investment amounts to EUR 1.5 million for 51 percent of the company and is made through a new issue. Pixel.bet's vision is to create the greatest gaming experience in betting on esports www.pixel.bet "Esports is an international and fast-growing area that engages millions of viewers and players every month. With this investment in Pixel.bet we as a Group will gain unique insight into a new and fast-growing segment," comments Gustaf Hagman, LeoVegas' Group CEO and co-founder of LeoVegas Mobile Gaming Group. "In Pixel.bet we have found a passionate team of entrepreneurs who come from the esports community. With its strong technology and mobile-first gaming experience, Pixel.bet is a perfect match for the LeoVegas Mobile Gaming Group. Together we will drive development for the absolute premier exp

LeoVegas AB: LeoVentures investerar i esport betting - Pixel.bet13.9.2018 08:45Pressmeddelande

LeoVegas-koncernen har, genom sitt helägda investmentbolag LeoVentures Ltd förvärvat Pixel Holding Group Ltd, som driver esport betting operatören pixel.bet. Investeringen uppgår till 1,5 miljoner euro för 51 procent av bolaget och görs genom en nyemission. Pixel.bets vision är att skapa den främsta spelupplevelsen inom betting på esport www.pixel.bet "Esport är ett internationellt och snabbt växande område som engagerar miljontals tittare och utövare varje månad. Med investeringen i Pixel.bet får vi som koncern en unik inblick i ett nytt och snabbt växande segment.", säger Gustaf Hagman, Group CEO och co-founder av LeoVegas Mobile Gaming Group. "I Pixel.bet fann vi ett passionerat entreprenörsteam som verkligen kommer inifrån esport communityn. Med en riktigt bra teknik och spelupplevelse utvecklad mobile-first är det en perfekt match med LeoVegas Mobile Gaming Group. Tillsammans ska vi driva utveckling för den absolut främsta upplevelsen inom esport betting.", säger Robin Ramm-Ericso

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum